VolitionRx Submits Manuscript for Nu.Q® Vet Feline Cancer Test in Cats
VolitionRx Limited (VNRX) submitted a clinical manuscript on its Nu.Q® Vet Feline prototype assay, which demonstrated high accuracy in detecting lymphoma in cats. The test has the potential to become the first affordable blood-based liquid biopsy for feline cancer and could unlock a $5 million milestone payment upon publication.
Topics: biotechnology cancer diagnostics liquid biopsy peer-reviewed study veterinary medicine